Journal Article

DZNE-2021-01545

http://join2-wiki.gsi.de/foswiki/pub/Main/Artwork/join2_logo100x88.png Association of plasma Aβ40/Aβ42 ratio and brain Aβ accumulation: testing a whole-brain PLS-VIP approach in individuals at risk of Alzheimer's disease.

Lemercier, P. ; Vergallo, A. ; Lista, S. ; Zetterberg, H. ; Blennow, K. ; Potier, M.-C. ; Habert, M.-O. ; Lejeune, F.-X. ; Dubois, B. ; Teipel, S.DZNE* ; Hampel, H. ; group, I. s. ; Initiative, t. A. P. M. (Collaboration Author)

2021
Elsevier Science Amsterdam [u.a.]

This record in other databases:    

Please use a persistent id in citations: doi:10.1016/j.neurobiolaging.2021.07.005

Abstract: Molecular and brain regional/network-wise pathophysiological changes at preclinical stages of Alzheimer's disease (AD) have primarily been found through knowledge-based studies conducted in late-stage mild cognitive impairment/dementia populations. However, such an approach may compromise the objective of identifying the earliest spatial-temporal pathophysiological processes. We investigated 261 individuals with subjective memory complaints, a condition at increased risk of AD, to test a whole-brain, non-a-priori method based on partial least squares in unraveling the association between plasma Aβ42/Aβ40 ratio and an extensive set of brain regions characterized through molecular imaging of Aβ accumulation and cortical metabolism. Significant associations were mapped onto large-scale networks, identified through an atlas and by knowledge, to elaborate on the reliability of the results. Plasma Aβ42/40 ratio was associated with Aβ-PET uptake (but not FDG-PET) in regions generally investigated in preclinical AD such as those belonging to the default mode network, but also in regions/networks normally not accounted - including the central executive and salience networks - which likely have a selective vulnerability to incipient Aβ accumulation. The present whole-brain approach is promising to investigate early pathophysiological changes of AD to fully capture the complexity of the disease, which is essential to develop timely screening, detection, diagnostic, and therapeutic interventions.

Keyword(s): Aged (MeSH) ; Alzheimer Disease: blood (MeSH) ; Alzheimer Disease: diagnosis (MeSH) ; Alzheimer Disease: metabolism (MeSH) ; Amyloid beta-Peptides: blood (MeSH) ; Amyloid beta-Peptides: metabolism (MeSH) ; Biomarkers: blood (MeSH) ; Biomarkers: metabolism (MeSH) ; Brain: diagnostic imaging (MeSH) ; Brain: metabolism (MeSH) ; Female (MeSH) ; Humans (MeSH) ; Male (MeSH) ; Peptide Fragments: blood (MeSH) ; Positron-Emission Tomography (MeSH) ; Risk (MeSH) ; Partial least square ; Plasma amyloid β ; Preclinical Alzheimer's disease ; Subjective memory complaints ; whole-brain

---

Contributing Institute(s):

1. Clinical Dementia Research Rostock /Greifswald (AG Teipel)

Research Program(s):

1. 353 - Clinical and Health Care Research (POF4-353) (POF4-353)

Appears in the scientific report 2021

---

Database coverage:
; ; ; BIOSIS Previews ; Biological Abstracts ; Clarivate Analytics Master Journal List ; Current Contents - Life Sciences ; Ebsco Academic Search ; Essential Science Indicators ; IF >= 5 ; JCR ; Nationallizenz ; SCOPUS ; Science Citation Index Expanded ; Web of Science Core Collection

---